Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
0.12%140.212.8%$312.44m
ZTSZoetis, Inc. Class A
-0.95%101.951.9%$203.67m
MYLMylan N.V.
-2.82%19.643.2%$182.09m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
1.84%11.632.0%$176.71m
TXMDTherapeuticsMD, Inc.
-3.48%3.3324.9%$12.94m
PETXAratana Therapeutics, Inc.
0.41%4.888.5%$10.31m
TAROTaro Pharmaceutical Industries Ltd.
-0.82%100.516.4%$6.46m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
-1.95%39.332.0%$5.61m
ABEOAbeona Therapeutics, Inc.
-0.13%7.447.6%$3.08m
KINKindred Biosciences, Inc.
-3.11%8.400.3%$1.61m
LFVNLifeVantage Corporation
-1.54%11.503.3%$1.37m
JAGXJaguar Animal Health, Inc.
25.73%0.219.8%$0.67m
CPHIChina Pharma Holdings, Inc.
-1.68%0.300.1%$0.13m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.